Suppr超能文献

瓣膜性心脏病的范式转变:指南应该向何处发展?

Evolving paradigms in valvular heart disease: where should guidelines move?

机构信息

William Harvey Research Institute, Queen Mary University of London, and Barts Heart Centre, London, United Kingdom.

出版信息

EuroIntervention. 2019 Nov 20;15(10):851-856. doi: 10.4244/EIJ-D-19-00818.

Abstract

The field of valve intervention is rapidly changing. Clinical practice guidelines are based on evidence and practical clinical experience. The randomised trials considered for the guideline recommendations regarding indications for TAVI cover the high-risk and intermediate-risk subgroups of patients. With new evidence for low-risk patients, consideration has to be given to discussing TAVI as the default strategy in the majority of patients. This is a paradigm shift from the established practice. More than ever, the patient will be at the centre of the decision making. The Heart Team is essential for optimal patient pathways, as patient factors, longevity and durability considerations have to inform the discussion. Further developments discussed in this article revolve around evidence on secondary mitral regurgitation and mitral edge-to-edge repair.

摘要

瓣膜介入领域正在迅速发展。临床实践指南基于证据和实际临床经验。指南推荐意见中关于 TAVI 适应证的随机试验涵盖了高危和中危亚组患者。随着低危患者新证据的出现,需要考虑将 TAVI 作为大多数患者的默认策略。这是从既定实践的范式转变。患者将比以往任何时候都更处于决策的中心。心脏团队对于优化患者路径至关重要,因为患者因素、寿命和耐用性考虑都需要纳入讨论。本文讨论的进一步发展围绕着二尖瓣反流和二尖瓣瓣环成形术的二级证据。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验